二线化疗对不可切除的晚期/复发性胃/食管胃交界癌（AGC）的影响仍不清楚。本回顾性分析旨在确定影响 AGC 患者化疗预后的因素，包括二线化疗中无进展生存期 (PFS-2) 的重要性。数据来自总共 109 名接受二线治疗的 AGC 患者进行分析的目的是阐明预后因素。此外，还研究了 PFS-2 与临床特征之间的相关性以及 PFS-2 与基于炎症和/或营养标记物之间的关联。多变量分析确定了以下预后因素：ECOG PS ≥1、存在腹膜播散、转移两个或多个器官，以及二线化疗中使用紫杉烷。在单变量分析中，短 PFS-2 与预后密切相关[风险比 (HR)=3.107，95% 置信区间 (CI)=1.969-4.904，p<0.001]。 PFS-2 的持续时间与 ECOG PS (p=0.019)、肝转移率 (p=0.035) 和二线化疗中紫杉烷的使用 (p=0.001) 显着相关。此外，一线治疗期间的体重减轻率（p=0.042）、白细胞计数（p=0.008）、C反应蛋白（p=0.032）、C反应蛋白与白蛋白比率（p=0.039）、预后指数 (p=0.028) 和改良格拉斯哥预后评分 (p=0.027) 与 PFS-2 持续时间显着相关。PFS-2 持续时间与 ECOG PS、肝转移和第二次紫杉烷使用显着相关。线治疗，并强烈影响 OS。有人认为，二线治疗开始时营养不良和炎症的存在会对 PFS-2 和 OS 产生负面影响。版权所有 © 2023 国际抗癌研究所（George J. Delinasios 博士），保留所有权利。

Impact of second-line chemotherapy in unresectable advanced/recurrent gastric/esophagogastric junction cancer (AGC) remains unclear. This retrospective analysis aimed to identify factors affecting prognosis in chemotherapy for patients with AGC, including the importance of progression-free survival in second-line chemotherapy (PFS-2).Data from a total of 109 patients with AGC that received second-line treatment were analyzed with the aim of clarifying prognostic factors. Furthermore, the correlation between PFS-2 and clinical characteristics and the association between PFS-2 and inflammation-based and/or nutritional markers were investigated.Multivariate analysis identified the following prognostic factors: ECOG PS ≥1, presence of peritoneal dissemination, metastasis in two or more organs, and taxane use on second-line chemotherapy. Short PFS-2 was strongly associated with prognosis in the univariate analysis [hazard ratio (HR)=3.107, 95% confidence interval (CI)=1.969-4.904, p<0.001]. The duration of PFS-2 was significantly correlated with ECOG PS (p=0.019), liver metastasis rates (p=0.035) and taxane use on second-line chemotherapy (p=0.001). In addition, weight loss rate during first-line treatment (p=0.042), white blood cell count (p=0.008), C-reactive protein (p=0.032), c-reactive protein to albumin ratio (p=0.039), prognostic index (p=0.028), and modified Glasgow prognostic score (p=0.027) were significantly associated with the duration of PFS-2.The duration of PFS-2 significantly correlated with ECOG PS, liver metastasis, and taxane use on second-line treatment, and strongly affected OS. It was suggested that the presence of malnutrition and inflammation at the start of second-line therapy had a negative impact on PFS-2 and OS.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.